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Abstract Objective: The aim of this study was to confirm the efficacy, safety, and
expected palatability of amlodipine orally disintegrating tablets (ODT)
[RACTAB formulation (Towa, Osaka, Japan)]. We report the re-analyzed
results of 1687 cases in clinical settings obtained through postmarketing
surveillance in Japan.
Method: Study subjects were patients receiving treatment for the first time
with amlodipine ODT for hypertension under routine care. A multicenter
central registration system was used for this prospective survey. The survey
was conducted fromOctober 2008 to October 2010. The observational period
was 12 weeks, during which time surveys on outpatient blood pressure, ad-
verse events, palatability, etc. were conducted.
Results: Blood pressure stabilized following treatment, and both systolic and
diastolic blood pressures were favorably controlled. Adverse events observed
were not significantly different from those observed during drug use trials of
amlodipine formulations reported in 2003. Moreover, palatability of amlo-
dipine ODT showed a 99.6% (227 of 228 cases) favorable patient acceptance,
which is consistent with the initial design concept of RACTAB formulation.
Conclusions: The results of this postmarketing surveillance study indicated
that the efficacy, safety, and palatability of amlodipine ODT met our ex-
pectations (dissolves quickly in the mouth, tastes good, and is not rough on
the tongue). Accordingly, amlodipine ODT are believed to be an easy-to-use
formulation for prescribing doctors, dispensing pharmacists, and patients
receiving treatment.
Introduction
Japan initiated its own universal medical care
insurance system in 1961, whereby the whole
population would receive equal medical care
when needed. This system earned praise around
the world.[1] However, Japan is no exception to
the growing costs of medical care, with healthcare
costs in 2009 reaching approximately f35 trillion,
representing an increase of 3.5% over 2008.[2] One
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reason for this is the aging of society and declin-
ing birth rate, which have been markedly high
in Japan. With the proportion of people aged
‡65 years being 22.7% in 2009, Japan has sud-
denly become an aged society in a manner un-
precedented in the rest of the world.[3] This has
increased the burden of insurance premiums on
the youth and is a problem that could threaten
the maintenance of the universal medical care
insurance system.
The Japanese government aims to alleviate
that burden and improve the financial state of the
medical insurance system without compromising
the quality of medical care and has started to re-
duce the cost of drugs included in medical care
costs by increasing the availability of generic
medicines (GEs). The cost of drugs accounts for
approximately 20% of overall medical care costs
in Japan, and according to the estimates of the
Japan Generic Medicines Association (Tokyo,
Japan), replacing long-term listed drugs with
substitutable GEs may reduce the annual costs of
drugs by more than f1 trillion.[4]
However, compared with Europe, the US, and
other countries, the use of GEs has not spread in
Japan as expected, and the GE market share
(based on sales volume) only increased by 0.8%
from 2003 to 2007 and remained at 17.2% in 2007.
Japan’s Ministry of Health, Labour and Wel-
fare (MHLW) has therefore set forth the ob-
jective of raising the market share of GEs to
‡30% of the sales volume by 2012. In 2007,
MHLW established the Action Programs for
Promoting Safe Use of Generic Medicine to
clarify the measures to be taken by state officials
and generic pharmaceutical product manu-
facturers.[5] The goal was to improve (i) quality
assurance; (ii) stable supply; (iii) supply of in-
formation; (iv) the environment for promoting
GE use; and (v) the medical insurance system to
help increase the GE market share.
RACTAB is a formulation technology for an
orally disintegrating tablet (ODT) that can be
consumed without water, disintegrates quickly in
a patient’s mouth,[6,7] and has characteristics such
as being less likely to chip or crack when being
supplied or dispensed,[8,9] and being versatile be-
cause of its simple manufacturing method.
Among all of the RACTAB formulations re-
leased in to the market, rough feeling on the
tongue is less with amlodipine ODTs because of
the particle diameter being £100 mm. Moreover,
the bitterness of the principal agent has been
masked.[10]
Objective
The objective of this study was to confirm the
efficacy, safety, and expected palatability of am-
lodipine ODT by re-analyzing the results of 1687
cases from a study of 2251 cases in clinical set-
tings.[11] In these 1687 cases, amlodipine ODT




The study subjects were patients who (i) switch-
ed to amlodipine ODT from another amlodipine
formulation (hereafter called substituted cases);
(ii) were receiving antihypertensive treatment for
the first time (hereafter called treatment-naı¨ve
cases); or (iii) switched to amlodipine ODT from
non-amlodipine formulations and/or were ad-
ministered with additional drugs etc. (hereafter
called remaining cases). A multicenter central
registration system was used for registration. The
registry period for postmarketing surveillance was
October 2008 to March 2010, and the survey
period for the current study was October 2008 to
October 2010. Because the study was an ob-
servational research of patients under routine care
in accordance with Good Postmarketing Study
Practice (GPSP) and not an interventional trial, no
informed consent was required from study partic-
ipants. Likewise, since the medication’s palatability
was reported by the doctor as a part of the patient
compliance instruction under routine care, no in-
formed consent was required.
During the observational period of 12 weeks,
surveys were conducted on patient background,
pretreatment drugs, administration of the study
drug with concomitant drugs, results of out-
patient blood pressure and heart rate tests, as well
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as drug monitoring investigations and adverse
events.
Of the 2251 cases investigated during post-
marketing surveillance, amlodipine ODT was
administered in 1687 cases (74.9%). Of these 1687
cases, 10 cases (0.6%) were excluded because the
cases had not been consulted since the first pre-
scription, and 11 cases (0.7%) were excluded
because of deviation from GPSP (either the pa-
tient had started treatment prior to agreement or
the registration period had deviated from the
time between the start of treatment and treat-
ment day 14). Therefore, 1666 cases were included
for safety evaluation. Of the 1666 cases, an ad-
ditional 120 cases (7.2%) were excluded from
efficacy evaluation because the readings of out-
patient blood pressure at treatment initiation or
after the treatment had started were unavailable;
therefore, 1546 cases were evaluated for efficacy
(figure 1).
Sex and age characteristics were studied in 812
men (48.7%) and 854 women (51.3%), with 695
patients (41.7%) aged <65 years and 971 patients
(58.3%) aged ‡65 years. Children (aged <15 years)
and pregnant women were not included. Of the
1666 patients, 423 patients (25.4%) were substituted
cases (amlodipine besylate had previously been
administered in these patients).
Of the 1546 cases evaluated for efficacy, 596
cases (38.6%) were treatment- naı¨ve cases and 399
(25.8%) were substituted cases.
Adverse Reactions
Of all the adverse drug reactions (ADRs) no-
ticed during the observation period, the present
text refers to those ADRs that can be classified
by the Medical Dictionary for Regulatory Ac-
tivities System Organ Class (MedDRA SOC)[12]
as nervous system disorders, heart and vascular
disorders, gastrointestinal disorders, skin and
subcutaneous tissue disorders, general disorders,
and administration site conditions. Among these,
dizziness, headache, arrhythmia, palpitations, feel-
ing of hot flushes, nausea and vomiting symptoms,
epidermal and dermal conditions, and asthenia have
been reported by the Risk/Benefit Assessment of
Drug - Analysis and Response (RAD-AR) Council
Number of cases for which questionnaires were collected: 2251 cases
(cases treated with amlodipine ODT [TOWA] and amlodipine tablets [TOWA])
Cases treated with amlodipine ODT (TOWA): 1687 cases
Cases for safety evaluation: 1666 cases
     substituted cases : 423 cases
     other cases: 1243 cases
Cases for efficacy evaluation: 1546 cases
     substituted cases: 399 cases
     treatment-naïve cases: 596 cases
     resta: 551 cases
a Cases of switch of medication from formulations other than amlodipine and those
with additional administered drugs.
Fig. 1. Case configuration.
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(Japan) to frequently begin during the early period
of antihypertensive drug administration.[13] When
analyzing the onset time from the initiation of
amlodipine ODT treatment, these ADRs were
classified as ‘ADRs occurring early in treatment’.
Palatability
To determine palatability (whether the medi-
cine was easy or difficult to ingest and the reasons
for this), doctors involved in the survey inter-
viewed patients by conducting a survey on the
method of ingestion and palatability of the med-




After treatment initiation, systolic and diastolic
blood pressures of the 596 treatment-naı¨ve cases
dropped significantly within 2 weeks (p< 0.001) and
then declined moderately until a favorably stabi-
lized transition was confirmed within 12 weeks. The
changes in systolic and diastolic blood pressures
between treatment initiation and after 12 weeks
varied from 163.9mmHg (95% CI 162.4, 165.4) to
136.3mmHg (95% CI 135.1, 137.4) and from
94.5mmHg (95%CI 93.5, 95.5) to 80.2mmHg (95%
CI 79.4, 81.1), respectively. In addition, heart rates
were stabilized within 12 weeks after treatment
initiation. In figure 2, the antihypertensive effect
on different original systolic blood pressures in the
329 cases (21.3%) in which a single drug dose of
5mg was administered is shown as an average
value from treatment initiation to the time of
final evaluation.When systolic blood pressure was
‡140mmHg at treatment initiation, a significant
antihypertensive effect was observed relative to
the blood pressure value before treatment.
In the 399 substituted cases, blood pressure
stabilized after substitution, and systolic and di-
astolic blood pressures were favorably control-
led. In addition, heart rates were stabilized within
12 weeks of treatment initiation (figure 3).
Safety
Incidence of Adverse Drug Reactions (ADRs)
ADRs were observed in 43 cases (an incidence
rate of 2.58%) of 1666 cases evaluated for safety.
Primary ADRs were nervous system disorders

























































Fig. 2. Cases where systolic blood pressure (SBP) has been lowered by the antihypertensive from treatment initiation (treatment-naı¨ve
cases: single drug [5mg] dose [non-substituted antihyperintensive]). Paired t-test (time of final observation vs time of treatment initiation).
NS = no significant difference; *** p< 0.001.
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or headaches, and abnormal test values (n= 8 cases;
0.48%), such as increased creatinine levels (table I).
Serious ADRs were reported to include one case
each of renal failure and arteriosclerosis obliterans,
but the causal determination of each physician was
‘probably not related’.
Among the substituted cases alone (n = 423
cases), ADRs were observed in seven cases (an
incidence rate of 1.65%) but no serious ADRs
were confirmed. The outcome of all seven cases
was ‘recovered’ or ‘recovering’, excluding one
case with an unknown outcome.
Onset Time of ADRs
In an analysis of the onset period of ‘ADRs
occurring early in treatment’ in the 1243 cases
other than the substituted cases in which amlo-
dipine besylate was first administered as the ac-
tive component, 32 ADR events were categorized
as ‘ADRs occurring early in treatment’. Of them,
81% (n = 26) were ADRs occurring in <4 weeks
of treatment initiation. Furthermore, of the
26 ADRs, 65% (n = 17) occurred in <2 weeks after
treatment initiation (figure 4).
On the other hand, in the 423 substituted cases,
five ADR events were categorized as ‘ADRs
occurring early in treatment’, with the onset in
<4 weeks in two cases (40%; one each of hypo-
tension and feeling of hot flushes) and <2 weeks
in one case (20%; feeling of hot flushes).
Palatability
Regarding the palatability of amlodipine ODT,
figure 5 shows the results of patient interviews
conducted by the doctors involved in the survey
12 weeks after treatment initiation or termination.
Of the 1355 cases in which a response was obtained
on palatability, 228 patients (16.8%) recorded that
the medicine was ‘mostly ingested without water’.
Among them, 227 (99.6%) found the medicine
‘easy to ingest’ and one (0.4%) found it ‘difficult to
ingest’. The reasons for the medicine being con-
sidered ‘easy to ingest’ included ‘dissolves quickly
in the mouth’ (170 cases), ‘tastes good’ (129 cases),
and ‘not rough on the tongue’ (56 cases), whereas
the reason for the medicine being considered ‘dif-
ficult to ingest’ was ‘tastes bad’.
Discussion
Efficacy
Blood pressure after treatment initiation in the
treatment-naı¨ve cases was favorably stabilized
139.2 140.7 136.4 135.7 136.5 135.9







*** *** *** ***
* *** ** *
n = 295 n = 399 n = 182 n = 344 n = 330 n = 323
74.3 73.9 73.9 73.2 73.5 73.3
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n = 175 n = 260 n = 112 n = 208 n = 194 n = 199
SBP
DBP
Fig. 3. Changes in blood pressure and heart rate (substituted cases). Average value and 95% confidence interval. Paired t-test (time of final
observation vs time of treatment initiation). DBP =diastolic blood pressure; NS = no significant difference; SBP = systolic blood pressure;
* p <0.05, ** p <0.01, *** p <0.001.
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Table I. Types of adverse drug reactions (ADRs)a,b
Substituted cases Cases other than substituted cases All cases
Cases for safety evaluation 423 1243 1666
No. of ADR cases (%) 7 (1.65) 36 (2.90) 43 (2.58)
No. of ADR events 8 53 61
Blood and lymphatic system disorders 1 (0.24) 0 1 (0.06)
Nephrogenic anaemia 1 (0.24) 0 1 (0.06)
Cardiac disorders 0 3 (0.24) 3 (0.18)
Palpitations 0 3 (0.24) 3 (0.18)
Tachycardiac 0 1 (0.08) 1 (0.06)
Gastrointestinal disorders 0 3 (0.24) 3 (0.18)
Angular stomatitisc 0 1 (0.08) 1 (0.06)
Enterocolitis 0 1 (0.08) 1 (0.06)
Queasy 0 1 (0.08) 1 (0.06)
General disorders and administration site conditions 1 (0.24) 2 (0.16) 3 (0.18)
Feels poorly 0 1 (0.08) 1 (0.06)
Edema 1 (0.24) 0 1 (0.06)
Edema lower limb 0 1 (0.08) 1 (0.06)
Hepatobiliary disorders 0 6 (0.48) 6 (0.36)
Hepatic function disorder 0 6 (0.48) 6 (0.36)
Investigations 0 8 (0.64) 8 (0.48)
Red blood cell count decreased 0 1 (0.08) 1 (0.06)
White blood cell increased 0 1 (0.08) 1 (0.06)
ALP increased 0 2 (0.16) 2 (0.12)
GGTP increase 0 1 (0.08) 1 (0.06)
LDH increased 0 1 (0.08) 1 (0.06)
BUN increased 0 2 (0.16) 2 (0.12)
Creatinine increased 0 3 (0.24) 3 (0.18)
Cholesterol levels raised 0 1 (0.08) 1 (0.06)
Lipids abnormalc 0 1 (0.08) 1 (0.06)
Sugar blood level increased 0 1 (0.08) 1 (0.06)
Metabolism and nutrition disorders 1 (0.24) 0 1 (0.06)
Hyperkalemiac 1 (0.24) 0 1 (0.06)
Nervous system disorders 1 (0.24) 11 (0.88) 12 (0.72)
Dizziness 0 3 (0.24) 3 (0.18)
Dizziness on standing up 1 (0.24) 0 1 (0.06)
Headache 0 4 (0.32) 4 (0.24)
Headache (dull) 0 1 (0.08) 1 (0.06)
Light-headed feeling 0 6 (0.48) 6 (0.36)
Renal and urinary disorders 1 (0.24) 1 (0.08) 2 (0.12)
Renal failurec 0 1 (0.08) 1 (0.06)
Renal failure chronic aggravated 1 (0.24) 0 1 (0.06)
Skin and subcutaneous tissue disorders 0 5 (0.40) 5 (0.30)
Itching 0 2 (0.16) 2 (0.12)
Redness 0 1 (0.08) 1 (0.06)
Rash 0 1 (0.08) 1 (0.06)
Photosensitive dermatitis 0 1 (0.08) 1 (0.06)
Continued next page
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within 12 weeks. Furthermore, an antihypertensive
effect on systolic blood pressure was observed in
those cases where a single drug dose of 5mg was
administered; the effect was relative to pretreat-
ment blood pressure values. In the substituted
cases, blood pressure stabilized after substitution
Table I. Contd
Substituted cases Cases other than substituted cases All cases
Vascular disorders 3 (0.71) 4 (0.32) 7 (0.42)
Feeling of hot flushes 1 (0.24) 0 1 (0.06)
Flushed face 0 2 (0.16) 2 (0.12)
Hypotension 1 (0.24) 1 (0.08) 2 (0.12)
Orthostatic hypotension 1 (0.24) 0 1 (0.06)
Arteriosclerosis obliterans 0 1 (0.08) 1 (0.06)
a Data are given as [no. of ADR events (%)], unless stated otherwise.
b Medical Dictionary for Regulatory Activities/J used for the types of side effects; bold numbers state number of cases for each system organ
class.
c Side effects that cannot be predicted from the precautions (predictability re-determined from the most recent Japanese package insert
[August 2010 revision]).

















a ADRs that frequently occur immediately after starting antihypertensive
administration are classified into nervous system disorders, heart or vascular
disorders, gastrointestinal disorders, skin and subcutaneous tissue disorders,
general disorders, and administration site conditions by the Medical Dictionary
for Regulatory Activities-System Organ Class. Among these, dizziness, headache,
arrhythmia, palpitations, hot flushes, nausea and vomiting, epidermal and dermal
conditions, and asthenia[12] have been reported by the Risk/Benefit Assessment
of Drugs-Analysis and Response Council.









ADRs occurring early in treatmenta
ADRs occurring after early in treatment
1b
Fig. 4. Onset of adverse drug reactions (ADRs) at different periods (excluding substituted cases).
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of medication, and systolic and diastolic blood
pressures were favorably controlled.
From these findings, amlodipine ODTwas con-
firmed to have an efficacy at clinical sites identi-
cal to that of amlodipine formulations from other
companies.[14,15] It was also confirmed to have
lowered blood pressure relative to that at treat-
ment initiation, without further increases in the
heart rate. Therefore, amlodipine ODT was con-
firmed as an easy-to-use antihypertensive that
moderately lowered blood pressure without bur-
dening the heart.
Safety
Of the 1666 cases, 43 ADRs (2.58%), primarily
nervous system disorders or abnormal test val-
ues, were observed. This, together with the onset
frequency and trend, was not significantly dif-
ferent from results reported in drug use trials of
other amlodipine formulations.
Patients who switched from amlodipine besylate
to amlodipine ODT had fewer ADRs occurring
more frequently in the early period of treatment
compared with those in whom amlodipine besy-
late was administered for the first time (non-
substituted cases [i.e. both treatment-naı¨ve and
remaining cases]) because amlodipine besylate
had already been administered as the active
component, although it was believed that the
distribution of suspected ADRs might be differ-
ent. Thus, ADRs reported[13] by the RAD-AR
Council in the Antihypertensive drug use trial
database construct research: final report as those
that frequently occurred immediately after begin-
ning treatment with antihypertensives and the
same ADRs deemed by MedDRA SOC as ‘ADRs
occurring early in treatment’ were analyzed for the
onset time. In our study, 32 ‘ADRs occurring early
in treatment’ (2.6%) occurred in the 1243 cases
(excluding the substituted cases). Of those, 81%
occurred in <4 weeks and 65% of those occurred in
<2 weeks. On the other hand, five corresponding
ADRs (1.2%) were observed in the 423 substituted
cases. Onset was observed in <44 weeks for a single
case each of hypotension and feeling of hot flushes,
and <2 weeks for a single case of feeling of hot
flushes. These results support the hypothesis of a
reduction in ADRs in patients who switched from
amlodipine besylate to amlodipine ODT.
These results suggest that no significant dif-
ference was observed in the onset of ADRs be-
tween amlodipine ODT and other amlodipine
formulations.[15] Furthermore, for substituted
cases whose data are unique to GEs, as expected,
‘ADRs occurring early in treatment’ had already
been experienced before the substitution took
place; therefore, fewer ADRs were observed than
when amlodipine besylate was first used as the
active component.
Difficult to ingest : 1 case
tastes bad: 1 case
Easy to ingest: 227 cases
       dissolves quickly in the mouth: 170 cases
       tastes good: 129 cases
       not rough on the tongue: 56 cases
       (duplicate aggregates)
Fig. 5. Amlodipine ODT palatability (228 patients took the tablets mostly without water). Reproduced from Towa Pharmaceutical Co., Ltd.,[11]
with permission.
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Palatability
Towa Pharmaceutical Co., Ltd.’s RACTAB
applies an intelligent formulation design to con-
ventional ODT formulation technology. It was
developed to increase usability and further enhance
medication adherence and a patient’s quality of life
with tablets that do not crack or chip in transit or in
automatic tablet-packaging machines.[8,9] In par-
ticular, amlodipine ODT disintegrates quickly be-
cause of its rapidly disintegrating particles. The
rough feeling on the tongue from some medication
is comparatively less with amlodipine ODT be-
cause its particle diameter is £100mm. It is less bit-
ter because the principal agent is masked.[7]
Therefore, in this study, a survey item was
established to confirm the medicine’s palatability
during actual use. The results showed that 99.6%
of patients (227 of 228 cases) rated amlodipine
ODT as ‘easy to ingest’ with regard to ease of con-
sumption when ingested mostly without water.
The reasons provided were that it ‘dissolves
quickly in the mouth’, ‘tastes good’, and ‘not
rough on the tongue’. Therefore, the RACTAB
formulation had favorable patient acceptance,
which is in line with its initial design concept. This
study also suggests that it is a formulation that
can be expected to enhance medication adherence
and quality of life.
Conclusion
In Japan, which has not had the same success
as other countries in promoting GEs, theMHLW
and Towa Pharmaceutical Co., Ltd. have an ob-
jective of increasing the use and improving the
reliability of GEs.
By re-analyzing the results obtained from Towa
Pharmaceutical Co., Ltd. postmarketing surveil-
lance of amlodipine ODT and amlodipine tablets,
the safety and efficacy of amlodipine ODT were
reaffirmed. Furthermore, it was possible to con-
firm the palatability of tablets formulated with
RACTAB technology, which has received high
praise in reviews for its design concept.[9] Accord-
ingly, amlodipine ODT is deemed to be a valuable
formulation for prescribing doctors, dispensing
pharmacists, and patients receiving treatment.
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